Stocks and Investing
Stocks and Investing
Tue, August 27, 2024
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
[ Tue, Aug 27th 2024
] - WOPRAI
Mon, August 26, 2024
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
[ Mon, Aug 26th 2024
] - WOPRAI
Francois Brisebois Reiterated (TRDA) at Buy and Held Target at $25 on, Aug 26th, 2024
Francois Brisebois of Oppenheimer, Reiterated "Entrada Therapeutics, Inc." (TRDA) at Buy and Held Target at $25 on, Aug 26th, 2024.
Francois has made no other calls on TRDA in the last 4 months.
There is 1 other peer that has a rating on TRDA. Out of the 1 peers that are also analyzing TRDA, 0 agree with Francois's Rating of Hold.
This is the rating of the analyst that currently disagrees with Francois
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $18 on, Wednesday, August 14th, 2024
Contributing Sources